Vandetanib for the treatment of lung cancer

Bibliography

• WHO. Cancer factsheet. 2009. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/ [Cited 15 June 2011]
   Google Scholar
• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin 2010;60(5):277-300
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parikh P, von Pawel J, Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26(21):3543-51
   PubMed Web of Science ®Google Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86(3):353-64
   PubMed Web of Science ®Google Scholar
• Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 2005;23(14):3243-56
   PubMed Web of Science ®Google Scholar
• Dvorak HF, Detmar M, Claffey KP, Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol 1995;107(1-3):233-5
   PubMed Web of Science ®Google Scholar
• Shimanuki Y, Takahashi K, Cui R, Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer. Lung 2005;183(1):29-42
   PubMed Web of Science ®Google Scholar
• Yuan A, Yu CJ, Kuo SH, Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 2001;19(2):432-41
   PubMed Web of Science ®Google Scholar
• Savai R, Langheinrich AC, Schermuly RT, Evaluation of angiogenesis using micro-computed tomography in a xenograft mouse model of lung cancer. Neoplasia 2009;11(1):48-56
   PubMed Web of Science ®Google Scholar
• Takayama K, Ueno H, Nakanishi Y, Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res 2000;60(8):2169-77
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50
   PubMed Web of Science ®Google Scholar
• Scagliotti G, Novello S, von Pawel J, Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28(11):1835-42
   PubMed Web of Science ®Google Scholar
• Blumenschein GR Jr, Kabbinavar F, Menon H, A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol 2011;22(9):2057-67
   PubMed Web of Science ®Google Scholar
• Amgen. A Phase III, multicenter, randomized, placebo-controlled, double-blind trial of AMG 706 in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer
   Google Scholar
• Kim ES, Herbst RS, Wistuba II, The BATTLE Trial: personalizing therapy for lung cancer. Cancer Discov 2011;1:44-53
   PubMed Web of Science ®Google Scholar
• Tew WP, Gordon M, Murren J, Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin Cancer Res 2010;16(1):358-66
   PubMed Web of Science ®Google Scholar
• Sibilia M, Kroismayr R, Lichtenberger BM, The epidermal growth factor receptor: from development to tumorigenesis. Differentiation 2007;75(9):770-87
   PubMed Web of Science ®Google Scholar
• Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 2002;110(6):669-72
   PubMed Web of Science ®Google Scholar
• Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5(5):341-54
   PubMed Web of Science ®Google Scholar
• Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004;4(5):361-70
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21(14):2787-99
   PubMed Web of Science ®Google Scholar
• Pirker R, Pereira JR, Szczesna A, Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373(9674):1525-31
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353(2):123-32
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu YL, Chen G, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011;12(8):735-42
   PubMed Web of Science ®Google Scholar
• Kim ES, Hirsh V, Mok T, Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372(9652):1809-18
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361(10):947-57
   PubMed Web of Science ®Google Scholar
• Maemondo M, Inoue A, Kobayashi K, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362(25):2380-8
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Morita S, Yatabe Y, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010;11(2):121-8
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Varella-Garcia M, McCoy J, Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005;23(28):6838-45
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350(21):2129-39
   PubMed Web of Science ®Google Scholar
• Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev 2005;16(4-5):441-67
   PubMed Web of Science ®Google Scholar
• Takahashi M, Ritz J, Cooper GM. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 1985;42(2):581-8
   PubMed Web of Science ®Google Scholar
• Wells SA Jr, Robinson BG, Gagel RF, Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012;30(2):134-41
   PubMed Web of Science ®Google Scholar
• Engelman JA, Janne PA, Mermel C, ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA 2005;102(10):3788-93
   PubMed Web of Science ®Google Scholar
• Pao W, Wang TY, Riely GJ, KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2(1):e17
   PubMed Web of Science ®Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316(5827):1039-43
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Boggon TJ, Dayaram T, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352(8):786-92
   PubMed Web of Science ®Google Scholar
• Pao W, Miller VA, Politi KA, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2(3):e73
   PubMed Web of Science ®Google Scholar
• Amin DN, Hida K, Bielenberg DR, Klagsbrun M. Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res 2006;66(4):2173-80
   PubMed Web of Science ®Google Scholar
• Solorzano CC, Baker CH, Tsan R, Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma. Clin Cancer Res 2001;7(8):2563-72
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Caputo R, Bianco R, Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 2001;7(5):1459-65
   PubMed Web of Science ®Google Scholar
• Hirata A, Ogawa S, Kometani T, ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002;62(9):2554-60
   PubMed Web of Science ®Google Scholar
• Luwor RB, Lu Y, Li X, The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene 2005;24(27):4433-41
   PubMed Web of Science ®Google Scholar
• Pore N, Jiang Z, Gupta A, EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res 2006;66(6):3197-204
   PubMed Web of Science ®Google Scholar
• Natale RB. Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer. J Thorac Oncol 2008;3(6 Suppl 2):S128-30
   PubMed Web of Science ®Google Scholar
• Naumov GN, Nilsson MB, Cascone T, Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 2009;15(10):3484-94
   PubMed Web of Science ®Google Scholar
• Wedge SR, Ogilvie DJ, Dukes M, ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62(16):4645-55
   PubMed Web of Science ®Google Scholar
• Carlomagno F, Vitagliano D, Guida T, ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002;62(24):7284-90
   PubMed Web of Science ®Google Scholar
• Holden SN, Eckhardt SG, Basser R, Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005;16(8):1391-7
   PubMed Web of Science ®Google Scholar
• Tamura T, Minami H, Yamada Y, A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 2006;1(9):1002-9
   PubMed Web of Science ®Google Scholar
• de Boer R, Humblet Y, Wolf J, An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer. Ann Oncol 2009;20(3):486-91
   PubMed Web of Science ®Google Scholar
• Blackhall FH, O'Brien M, Schmid P, A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer. J Thorac Oncol 2010;5(8):1285-8
   PubMed Web of Science ®Google Scholar
• Heymach JV, Johnson BE, Prager D, Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007;25(27):4270-7
   PubMed Web of Science ®Google Scholar
• Heymach JV, Paz-Ares L, De Braud F, Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008;26(33):5407-15
   PubMed Web of Science ®Google Scholar
• Kiura K, Nakagawa K, Shinkai T, A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol 2008;3(4):386-93
   PubMed Web of Science ®Google Scholar
• Natale RB, Bodkin D, Govindan R, Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol 2009;27(15):2523-9
   PubMed Web of Science ®Google Scholar
• Lee JS, Hirsh V, Park K, Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2012;30(10):1114-21
   PubMed Web of Science ®Google Scholar
• Natale RB, Thongprasert S, Greco FA, Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011;29(8):1059-66
   PubMed Web of Science ®Google Scholar
• Herbst RS, Sun Y, Eberhardt WE, Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010;11(7):619-26
   PubMed Web of Science ®Google Scholar
• de Boer RH, Arrieta O, Yang CH, Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011;29(8):1067-74
   PubMed Web of Science ®Google Scholar
• Herbst RS. Toxicities of antiangiogenic therapy in non-small-cell lung cancer. Clin Lung Cancer 2006;8(Suppl 1):S23-30
   PubMed Web of Science ®Google Scholar
• Ricciardi S, Tomao S, de Marinis F. Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer 2009;10(1):28-35
   PubMed Web of Science ®Google Scholar
• AstraZeneca. AstraZeneca withdraws regulatory submissions for Zactima (vandetanib) in combination with chemotherapy for advanced NSCLC. 2009. Available from: http://www.astrazeneca.com/Media/Press-releases/Article/20091028--AstraZeneca-withdraws-regulatory-submissions-for-Zact
   Google Scholar
• Kwak EL, Bang YJ, Camidge DR, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693-703
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448(7153):561-6
   PubMed Web of Science ®Google Scholar